MetaCap

Cue Biopharma (CUE) vs Pliant Therapeutics (PLRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pliant Therapeutics (PLRX) has outperformed Cue Biopharma (CUE) over the past year, losing 61.6% versus a loss of 76.8%. Over five years, PLRX leads with a -95.9% price change compared with -98.9% for CUE. Pliant Therapeutics is the larger company by market cap ($36.9 million vs $34.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CUE-76.75%PLRX-61.61%
+122%+14%-94%
Nov 21, 20251 yearNov 20, 2026
CUE-99.07%PLRX-96.03%
+144%+17%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CUE versus PLRX key metrics
MetricCUEPLRX
Share price$4.15$0.5951
Market cap$34.69M$36.89M
1-day change-7.78%-4.02%
YTD return-54.64%-51.22%
1-year return-76.75%-61.61%
5-year return-98.92%-95.89%
EPS (TTM)$-27.80$-1.46
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$27.47M$0
Revenue growth (YoY)+195.75%—
Net income (latest FY)$-26.60M$-149.34M
Operating margin-96.67%—
Net margin-96.85%—
52-week high$45.50$1.67
52-week low$2.83$0.5719
Distance from 52-week high-90.88%-64.37%
Analyst consensusnonenone
Avg. price target upside+2020.48%+236.08%
Average volume567.02K408.93K
Shares outstanding8.36M61.99M
Employees2949
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PLRX has outperformed CUE by 15.1 percentage points over the past year.

About Cue Biopharma

CUE stock →

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

About Pliant Therapeutics

PLRX stock →

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees

CUE vs PLRX FAQ

Which is bigger, Cue Biopharma or Pliant Therapeutics?

Pliant Therapeutics (PLRX) is larger, with a market capitalization of $36.89M compared with $34.69M for Cue Biopharma (CUE).

Which stock has performed better over the past year, CUE or PLRX?

PLRX returned -61.61% over the past 12 months, compared with -76.75% for CUE (price return, excluding dividends). Past performance does not predict future results.

Are Cue Biopharma and Pliant Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons